CN116350548A - Skin-moistening emulsion and preparation method thereof - Google Patents
Skin-moistening emulsion and preparation method thereof Download PDFInfo
- Publication number
- CN116350548A CN116350548A CN202310408337.5A CN202310408337A CN116350548A CN 116350548 A CN116350548 A CN 116350548A CN 202310408337 A CN202310408337 A CN 202310408337A CN 116350548 A CN116350548 A CN 116350548A
- Authority
- CN
- China
- Prior art keywords
- added amount
- emulsifying pot
- added
- stirring
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000000839 emulsion Substances 0.000 title description 3
- 238000004945 emulsification Methods 0.000 title description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 25
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 22
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 20
- -1 coco glucoside Chemical compound 0.000 claims abstract description 15
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 13
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 13
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims abstract description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940008099 dimethicone Drugs 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 11
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 11
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000458 allantoin Drugs 0.000 claims abstract description 11
- 229940082500 cetostearyl alcohol Drugs 0.000 claims abstract description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims abstract description 11
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 11
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000008524 evening primrose extract Nutrition 0.000 claims abstract description 11
- 229940089020 evening primrose oil Drugs 0.000 claims abstract description 11
- 239000010475 evening primrose oil Substances 0.000 claims abstract description 11
- 235000011187 glycerol Nutrition 0.000 claims abstract description 11
- 229960005150 glycerol Drugs 0.000 claims abstract description 11
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 11
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 11
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 11
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960001295 tocopherol Drugs 0.000 claims abstract description 11
- 229930003799 tocopherol Natural products 0.000 claims abstract description 11
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 11
- 239000011732 tocopherol Substances 0.000 claims abstract description 11
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000230 xanthan gum Substances 0.000 claims abstract description 11
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 11
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 11
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 11
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims abstract description 10
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 10
- 229940080421 coco glucoside Drugs 0.000 claims abstract description 10
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims abstract description 10
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 10
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims abstract description 10
- 229960002216 methylparaben Drugs 0.000 claims abstract description 10
- 229940100460 peg-100 stearate Drugs 0.000 claims abstract description 10
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 10
- 229960003415 propylparaben Drugs 0.000 claims abstract description 10
- 229940075529 glyceryl stearate Drugs 0.000 claims abstract description 8
- 229960004063 propylene glycol Drugs 0.000 claims abstract description 7
- 235000013772 propylene glycol Nutrition 0.000 claims abstract description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 18
- 239000006210 lotion Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000012636 effector Substances 0.000 abstract description 7
- 102000003918 Hyaluronan Synthases Human genes 0.000 abstract description 6
- 108090000320 Hyaluronan Synthases Proteins 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 241000252212 Danio rerio Species 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 101710197055 Hyaluronan synthase 3 Proteins 0.000 description 2
- 102100029425 Hyaluronan synthase 3 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000005523 excessive nutrition Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108091035155 miR-10a stem-loop Proteins 0.000 description 1
- 108091084882 miR-10a-1 stem-loop Proteins 0.000 description 1
- 108091088205 miR-10a-2 stem-loop Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the technical field of skin care products, in particular to skin care cream and a preparation method thereof. The invention comprises the following components: cetostearyl alcohol, caprylic/capric triglyceride, cyclopentadimethicone, liquid paraffin, ethylhexyl palmitate, dimethicone, evening primrose oil, coco glucoside, tocopherol, PEG-100 stearate, glyceryl stearate, propyl hydroxybenzoate, xanthan gum, glycerin, propylene glycol, allantoin, water, methylparaben, disodium EDTA, dipotassium glycyrrhizinate, and phenoxyethanol. According to the invention, by aiming at effector cells, research (HAS 3 hyaluronic acid synthetase 3) is carried out, and simplified compatibility is carried out on the effector cells in terms of components, so that the skin metabolism burden can be reduced, and the product efficiency and the effect stability can be improved.
Description
Technical Field
The invention relates to the technical field of skin care products, in particular to skin care cream and a preparation method thereof.
Background
Psoriasis, atopic dermatitis and eczema are skin diseases caused by immune abnormality, in Atopic Dermatitis (AD)/eczema, due to abnormal regulation of microRNA after transcription, miR-10a-5p is abnormally up-regulated, and the expression of a direct target HAS3 (hyaluronic acid synthetase 3) is abnormal, so that skin dryness and skin barrier damage are caused. In clinical treatment, patients are required to be in daily moisture care.
However, the existing moisturizing products are all studied from the aspect of component efficacy, such as that a certain raw material has moisturizing efficacy and a certain raw material has soothing efficacy. No targeted research on effector cells which cut clinical practical demands is performed, so that the problems of unstable product effect, poor product pertinence or increased skin burden caused by excessive nutrition are caused.
Disclosure of Invention
The invention aims to provide a skin lotion and a preparation method thereof, which are used for solving the problems in the background technology.
In order to achieve the above purpose, the present invention provides the following technical solutions:
a skin lotion comprising the following components:
cetostearyl alcohol, caprylic/capric triglyceride, cyclopentadimethicone, liquid paraffin, ethylhexyl palmitate, dimethicone, evening primrose oil, coco glucoside, tocopherol, PEG-100 stearate, glyceryl stearate, propyl hydroxybenzoate, xanthan gum, glycerin, propylene glycol, allantoin, water, methylparaben, disodium EDTA, dipotassium glycyrrhizinate, and phenoxyethanol.
Further, the cetostearyl alcohol is added in an amount of 0.001-10% by mass, the caprylic/capric triglyceride is added in an amount of 0.001-10% by mass, the cyclopentadimethicone is added in an amount of 0.001-10% by mass, the liquid paraffin is added in an amount of 0.001-10% by mass, the ethylhexyl palmitate is added in an amount of 0.001-10% by mass, the dimethicone is added in an amount of 0.001-10% by mass, the evening primrose oil is added in an amount of 0.001-10% by mass, the cocoyl glucoside is added in an amount of 0.001-10% by mass, the tocopherol is added in an amount of 0.001-10% by mass, the xanthan gum is added in an amount of 0.001-10% by mass, the glycerin is added in an amount of 0.001-10% by mass, the propylene glycol is added in an amount of 0.001-10% by mass, the allantoin is added in an amount of 0.001-10% by mass, and the dipotassium glycyrrhizinate is added in an amount of 0.001-10% by mass.
A preparation method of skin lotion is used for the skin lotion, and comprises the following steps:
the first step: adding cetostearyl alcohol, caprylic/capric triglyceride, cyclopentadimethicone, liquid paraffin, ethylhexyl palmitate, dimethicone, evening primrose oil, coco glucoside, tocopherol, PEG-100 stearate, glyceryl stearate and propyl hydroxy benzoate into an oil phase pot, stirring and heating to 80 ℃;
and a second step of: adding water into an emulsifying pot, sequentially adding xanthan gum, glycerol, propylene glycol, allantoin, methylparaben and disodium EDTA into the emulsifying pot, stirring and heating to 85 ℃, adding the materials in the oil phase pot into the emulsifying pot, homogenizing for 5 minutes, and then carrying out heat preservation and stirring, wherein the stirring speed of the emulsifying pot is 30r/min;
and a third step of: adding dipotassium glycyrrhizinate into an emulsifying pot, starting a vacuum pump for vacuumizing, and preserving heat for 20 minutes at 80 ℃;
fourth step: cooling and stirring, wherein the stirring speed of the emulsifying pot is 30r/min;
fifth step: after the temperature is reduced to 45 ℃, phenoxyethanol is added into an emulsifying pot and then stirred for 10 minutes;
sixth step: filtering and discharging after the temperature is reduced to below 35 ℃.
Compared with the prior art, the invention has the beneficial effects that:
according to the invention, by aiming at effector cells, research (HAS 3 hyaluronic acid synthetase 3) is carried out, and simplified compatibility is carried out on the effector cells in terms of components, so that the skin metabolism burden can be reduced, and the product efficiency and the effect stability can be improved.
Drawings
FIG. 1 is a graph showing the relative expression level of the has3 gene of the present invention.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Embodiment one:
a skin lotion comprising the following components:
cetostearyl alcohol, caprylic/capric triglyceride, cyclopentadimethicone, liquid paraffin, ethylhexyl palmitate, dimethicone, evening primrose oil, coco glucoside, tocopherol, PEG-100 stearate, glyceryl stearate, propyl hydroxybenzoate, xanthan gum, glycerin, propylene glycol, allantoin, water, methylparaben, disodium EDTA, dipotassium glycyrrhizinate, and phenoxyethanol.
Wherein, water is solvent; the methylparaben, the propylparaben and the phenoxyethanol are all preservatives, and the PEG-100 stearate and the glycerol stearate are all emulsifying agents; disodium EDTA is a chelating agent.
The addition amount of cetostearyl alcohol may be 0.001-10% by mass, the addition amount of caprylic/capric triglyceride may be 0.001-10% by mass, the addition amount of cyclopenta-dimethicone may be 0.001-10% by mass, the addition amount of liquid paraffin may be 0.001-10% by mass, the addition amount of ethylhexyl palmitate may be 0.001-10% by mass, the addition amount of polydimethylsiloxane may be 0.001-10% by mass, the addition amount of evening primrose oil may be 0.001-10% by mass, the addition amount of coco-glucoside may be 0.001-10% by mass, the addition amount of tocopherol may be 0.001-10% by mass, the addition amount of xanthan gum may be 0.001-10% by mass, the addition amount of glycerin may be 0.001-10% by mass, the addition amount of propylene glycol may be 0.001-10% by mass, the addition amount of allantoin may be 0.001-10% by mass, and the addition amount of dipotassium glycyrrhizinate may be 0.001-10% by mass.
In this example, the added amount of cetostearyl alcohol is specifically 5%, the added amount of caprylic/capric triglyceride is specifically 5%, the added amount of cyclopenta-dimethicone is specifically 5%, the added amount of liquid paraffin is specifically 6%, the added amount of ethylhexyl palmitate is specifically 5%, the added amount of dimethicone is specifically 5%, the added amount of evening primrose oil is specifically 6%, the added amount of coco glucoside is specifically 6%, the added amount of tocopherol is specifically 5%, the added amount of xanthan gum is specifically 3%, the added amount of glycerin is specifically 3%, the added amount of propylene glycol is specifically 3%, the added amount of allantoin is specifically 5%, and the added amount of dipotassium glycyrrhizinate is specifically 6% in terms of mass fraction; the remainder was made up of water, methylparaben, disodium EDTA, PEG-100 stearate, glyceryl stearate, propylparaben and phenoxyethanol.
In this example, the amounts of water, methylparaben, disodium EDTA, PEG-100 stearate, glycerol stearate, propylparaben and phenoxyethanol added were all added in the amounts commonly used in the industry. Since the ratio of the addition amounts of these components does not affect the use effect of the present product, it may be arbitrarily increased or decreased in other embodiments.
Referring to fig. 1, a normal control group, a model control group and a sample group of the product are sequentially shown from left to right in the figure;
effect experiment:
zebra fish treated with sodium chloride will shrink the skin surface due to osmotic pressure. Hyaluronic Acid (HA) exists in dermis layers of skin and HAs a moisturizing function. Hyaluronic acid synthase 3 (Hyaluronan synthase 3, HAS 3), an enzyme molecule involved in the synthesis of hyaluronic acid, is responsible for the synthesis of low molecular weight hyaluronic acid (100-1000 ku). HAS3 is expressed in many tissues at the end of embryo and in adults, can spontaneously act on the matrix surrounding the cells, and can bind to the cell surface HS receptor, trigger a signaling cascade, and produce various physiological effects in the cells. Therefore, by detecting the relative expression level of the has3 gene, whether the sample has moisturizing effect can be indicated.
1. Zebra fish were randomly selected in 6-well plates with 30 tails per well.
2. The samples of the product were given water-soluble, and a normal control group and a model control group were simultaneously set, with a capacity of 3mL per well. Three biological replicates.
3. Meanwhile, sodium chloride is given by water dissolution to establish a zebra fish skin water deficiency model.
Incubate at 4.28℃for 22h in the absence of light.
5. Extracting total RNA of zebra fish of each experimental group, synthesizing cDNA, and detecting gene expression of beta-actin and target genes by q-PCR.
6. The relative expression quantity of RNA of the target gene is calculated by using beta-actin as an internal reference of gene expression.
RNA relative expression amount=2 ΔΔC(t)
ΔC(t)＝C(t) Target gene -C(t) β-actin
The judgment basis is that the statistical analysis p is less than 0.05, and the judgment is that the significant difference exists.
Conclusion of experiment: the observation shows that the relative expression quantity of the has3 gene of the sample group of the product is obviously increased compared with that of the model control group, and the product has the moisturizing effect.
Embodiment two:
on the basis of the first embodiment, the preparation method of the skin-moistening emulsion is disclosed, and specifically comprises the following steps:
the first step: adding cetostearyl alcohol, caprylic/capric triglyceride, cyclopentadimethicone, liquid paraffin, ethylhexyl palmitate, dimethicone, evening primrose oil, coco glucoside, tocopherol, PEG-100 stearate, glyceryl stearate and propyl hydroxy benzoate into an oil phase pot, stirring and heating to 80 ℃;
and a second step of: adding water into an emulsifying pot, sequentially adding xanthan gum, glycerol, propylene glycol, allantoin, methylparaben and disodium EDTA into the emulsifying pot, stirring and heating to 85 ℃, adding the materials in the oil phase pot into the emulsifying pot, homogenizing for 5 minutes, and then carrying out heat preservation and stirring, wherein the stirring speed of the emulsifying pot is 30r/min;
and a third step of: adding dipotassium glycyrrhizinate into an emulsifying pot, starting a vacuum pump for vacuumizing, and preserving heat for 20 minutes at 80 ℃;
fourth step: cooling and stirring, wherein the stirring speed of the emulsifying pot is 30r/min;
fifth step: after the temperature is reduced to 45 ℃, phenoxyethanol is added into an emulsifying pot and then stirred for 10 minutes;
sixth step: filtering and discharging after the temperature is reduced to below 35 ℃.
In summary, the invention can reduce the skin metabolism burden and improve the product efficiency and the effect stability by aiming at effector cells (HAS 3 hyaluronic acid synthase 3) and simplifying compatibility of the components aiming at the effector cells.
It is noted that relational terms such as first and second, and the like are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Moreover, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (3)
1. A skin lotion, which is characterized by comprising the following components:
cetostearyl alcohol, caprylic/capric triglyceride, cyclopentadimethicone, liquid paraffin, ethylhexyl palmitate, dimethicone, evening primrose oil, coco glucoside, tocopherol, PEG-100 stearate, glyceryl stearate, propyl hydroxybenzoate, xanthan gum, glycerin, propylene glycol, allantoin, water, methylparaben, disodium EDTA, dipotassium glycyrrhizinate, and phenoxyethanol.
2. The skin care lotion according to claim 1, wherein the added amount of cetostearyl alcohol is 0.001 to 10%, the added amount of caprylic/capric triglyceride is 0.001 to 10%, the added amount of cyclopentadimethicone is 0.001 to 10%, the added amount of liquid paraffin is 0.001 to 10%, the added amount of ethylhexyl palmitate is 0.001 to 10%, the added amount of dimethicone is 0.001 to 10%, the added amount of evening primrose oil is 0.001 to 10%, the added amount of coco glucoside is 0.001 to 10%, the added amount of tocopherol is 0.001 to 10%, the added amount of xanthan gum is 0.001 to 10%, the added amount of glycerin is 0.001 to 10%, the added amount of propylene glycol is 0.001 to 10%, the added amount of allantoin is 0.001 to 10%, and the added amount of dipotassium glycyrrhizinate is 0.001 to 10%.
3. A method of preparing a skin lotion for use in a skin lotion according to any one of claims 1 or 2, comprising the steps of:
s1: adding cetostearyl alcohol, caprylic/capric triglyceride, cyclopentadimethicone, liquid paraffin, ethylhexyl palmitate, dimethicone, evening primrose oil, coco glucoside, tocopherol, PEG-100 stearate, glyceryl stearate and propyl hydroxy benzoate into an oil phase pot, stirring and heating to 80 ℃;
s2: adding water into an emulsifying pot, sequentially adding xanthan gum, glycerol, propylene glycol, allantoin, methylparaben and disodium EDTA into the emulsifying pot, stirring and heating to 85 ℃, adding the materials in the oil phase pot into the emulsifying pot, homogenizing for 5 minutes, and then carrying out heat preservation and stirring, wherein the stirring speed of the emulsifying pot is 30r/min;
s3: adding dipotassium glycyrrhizinate into an emulsifying pot, starting a vacuum pump for vacuumizing, and preserving heat for 20 minutes at 80 ℃;
s4: cooling and stirring, wherein the stirring speed of the emulsifying pot is 30r/min;
s5: after the temperature is reduced to 45 ℃, phenoxyethanol is added into an emulsifying pot and then stirred for 10 minutes;
s6: filtering and discharging after the temperature is reduced to below 35 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310408337.5A CN116350548A (en) | 2023-04-17 | 2023-04-17 | Skin-moistening emulsion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310408337.5A CN116350548A (en) | 2023-04-17 | 2023-04-17 | Skin-moistening emulsion and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116350548A true CN116350548A (en) | 2023-06-30 |
Family
ID=86916270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310408337.5A Pending CN116350548A (en) | 2023-04-17 | 2023-04-17 | Skin-moistening emulsion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116350548A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412015A (en) * | 2017-05-04 | 2017-12-01 | 广州诺胜化妆品有限公司 | A kind of skin barrier repairs breast and preparation method |
-
2023
- 2023-04-17 CN CN202310408337.5A patent/CN116350548A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412015A (en) * | 2017-05-04 | 2017-12-01 | 广州诺胜化妆品有限公司 | A kind of skin barrier repairs breast and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 北京中研创科医疗科技有限公司: "宜科欣轻盈保湿润肤乳", pages 1, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakan.html?prodId=1089845628302786560&gb=G> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101482800B1 (en) | Novel low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition, and food composition each using same | |
| JP4953203B2 (en) | Composition containing hyaluronic acid production promoting factor obtained from persimmon and use thereof | |
| US20100028471A1 (en) | Cosmetic use of active agents that stimulate matriptase expression | |
| JP2012241192A (en) | Hyaluronic acid ester, production thereof and use in dermatology | |
| CN108434064A (en) | Have both the skin care item of skin anti-inflammatory Eradicates acnes and repair function | |
| CN110731923A (en) | Enhanced moisturizing cosmetic compositions | |
| CN116350548A (en) | Skin-moistening emulsion and preparation method thereof | |
| EP3574022B1 (en) | Hyaluronic acid cross-linked with natural or semi-synthetic crosslinking agents | |
| CN102349944A (en) | Nasal thermosensitive in-situ gel prepared by radix scutellariae extract, its preparation method and its application | |
| Zhang et al. | Intra-articular delivery system of methotrexate for rheumatoid arthritis therapy: An in-suit thermosensitive comprehensive gel of polysaccharide from Aconitum carmichaelii Debx. | |
| KR20220052965A (en) | Skin care composition comprising mevalonolactone | |
| EP2935199B1 (en) | Esters of glycyrrhetinic acid, preparation and cosmetic applications thereof | |
| Postoy et al. | Study of rheological behaviour of hydroxyethyl cellulose gels in the development of the composition and technology of the medicine with anti-inflammatory activity | |
| JPH08143462A (en) | Immunostimulating agent and antitumor agent | |
| KR101421499B1 (en) | An agent which promotes production of collagen, a cosmetic agent, a method for producing collagen | |
| CN102688178B (en) | Application of rape bee pollen extract in anti-aging skin care products | |
| JP3073862B2 (en) | Hyaluronic acid production promoter | |
| CN102846558B (en) | Lornoxicam freeze-drying preparation and preparation method thereof | |
| CN102416026B (en) | Preparation method of nano ginkgo leaf extract external preparation | |
| CN102188350B (en) | Rape bee pollen extract as well as preparation method and application thereof in anti-aging skincare products | |
| KR101892641B1 (en) | Skin External Composition Containing Ulmus Davidiana Extract, Dioscorea Japonica Extract or Morus Alba Leaf Extract | |
| CN112891294B (en) | Acne-removing scar-eliminating repairing skin-care composition and acne-removing cream and emulsion containing same | |
| JP2015063510A (en) | Moisture retention-related gene expression promoter involved in improved moisture retention function of skin | |
| CN115645367B (en) | Astaxanthin hyaluronic acid ester, preparation method of micelle and application of astaxanthin hyaluronic acid ester and micelle | |
| CN117919115B (en) | Skin care type skin plastid, preparation method and application thereof in cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |